Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer.
Heather J ChalfinTiziano PramparoAmir MortazaviScot A NiglioJoseph D SchonhoftAdam JendrisakYen-Lin ChuRobin RichardsonRachel KrupaAmanda K L AndersonYipeng WangRyan DittamoreSumanta K PalPrimo N LaraMark N SteinDavid I QuinnSeth M SteinbergLisa M CordesLisa LeyMarissa MallekOlena Sierra OrtizRene CostelloJacqueline CadenaCarlos DiazJames L GulleyWilliam L DahutHoward StreicherJohn J WrightJane B TrepelDonald P BottaroAndrea B ApoloPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Shorter survival may be associated with high CTC counts at baseline, presence of specific CTC morphologic subtypes, PD-L1+ CTCs, and low %CD4/8 T cells in patients with metastatic genitourinary cancer. A future study is warranted to validate the prognostic utility of CTC heterogeneity and detection of specific CTC morphologies.